Top 10 chemical injection products have been produced in the market of 600 billion yuan, only 10 products have been evaluated

Recently, Chengdu Beite Pharmaceutical Co., Ltd.'s ketorolac aminobutanol injection was approved with three types of generic listing applications, and deemed to have passed the consistency evaluation According to the latest data of mienei.com, at present, there are 10 injections that have passed or deemed to have passed the consistency evaluation, 92 supplementary applications for consistency evaluation of injection products are in the review and approval (in the drug Audit Center), and 9 major products of pharmaceutical enterprises are "clustered" In 2018, the sales volume of terminal drug injections of public medical institutions in China exceeded 600 billion yuan Among the top 10 brands, 7 are foreign-funded brands except dizosin injection of Yangtze River Pharmaceutical Group, ceftazidime for injection of Hainan Hailing chemical pharmaceutical and sodium chloride injection of Sichuan Kelun pharmaceutical Among them, only the sales volume of dizosin injection of Yangzijiang pharmaceutical group exceeded 5 billion yuan, ranking first In the 600 billion chemical injection Market, the sales of urban public hospitals declined The sales of terminal chemical injection of Chinese public medical institutions (unit: 10000 yuan) in urban public hospitals of China in 2018 , county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have a sales volume of 615.157 billion yuan, up 3.94% year-on-year In recent years, the growth rate of injection sales has slowed down From the perspective of the channel pattern, urban public hospitals undoubtedly rank first, but their market share has gradually declined, from 73.11% in 2013 to 68.65% in 2018, while the market share of county-level public hospitals and township hospitals has steadily increased Top 10 products 5 billion is the "threshold", Yangtze River, Kelun "Kill" encircles the top 10 (unit: 10000 yuan) of terminal drug injection products of public medical institutions in China In 2018, the sales volume of top 10 products exceeded 5 billion yuan, of which the sales volume of sodium chloride injection and human albumin exceeded 10 billion yuan The total sales of top 10 products reached 85.798 billion yuan, accounting for 14% of the sales of chemical injection In terms of product categories, blood and hematopoiesis system drugs and systemic anti infective drugs each have three on the list Among the top 10 brands (unit: 10000 yuan) of terminal drug injection brands of public medical institutions in China, 7 are foreign-funded brands except dizoxin injection of Yangtze River Pharmaceutical Group, ceftazidime for injection of Hainan Hailing Chemical Pharmaceutical Co., Ltd and sodium chloride injection of Sichuan Kelun Pharmaceutical Co., Ltd Among the three domestic brands, only the sales volume of dizosin injection of Yangzijiang pharmaceutical group exceeded 5 billion; the market share of ceftazidime hainaniling for injection ranked first with nearly 70%; the competition of sodium chloride injection was fierce, and the sales volume of Sichuan Kelun pharmaceutical industry increased steadily, and the market share of Sichuan Kelun pharmaceutical industry remained above 20% in recent years The channel pattern of dizosin injection at the end of China's public medical institutions dizosin injection is the exclusive product of Yangzijiang Pharmaceutical Group According to the data, dizosin was developed by Wyeth ayerst laboratory and listed in the United States in 1990 In 2009, dizosin injection produced by Yangzijiang Pharmaceutical Group was imitated for the first time According to the data of mienei.com, in recent years, the sales of dizosin injection has been growing rapidly with a double-digit growth rate Urban public hospitals and county-level public hospitals are the main sales channels of the product, with sales exceeding 5 billion yuan in 2018 At present, Tianjin Pharmaceutical Research Institute, Jiangsu Enhua pharmaceutical and other pharmaceutical enterprises have submitted the listing application for the variety Top 20 brand pattern of terminal sodium chloride injection in public medical institutions of China in 2018 According to the data of minenet, sodium chloride injection won the top sales of chemical injection products with 17.704 billion yuan At present, there are nearly 900 approvals for this product and more than 250 manufacturers Among them, the sales of Sichuan Kelun pharmaceutical, Shijiazhuang No.4 pharmaceutical, Dazhong pharmaceutical and Shandong Qidu pharmaceutical are over 1 billion yuan, accounting for 44% of the total sales of sodium chloride injection In 2018, ceftazidime for injection, the top 20 brand of terminal ceftazidime injection in China's public medical institutions, belongs to systemic anti infective drugs, with more than 300 approvals, more than 80 manufacturers, and sales volume of more than 5 billion in recent years Hainan Hailing Chemical Pharmaceutical Co., Ltd accounts for nearly 70% of the market share At present, the supplementary application for conformity assessment of Qilu Pharmaceutical Co., Ltd., Hanmei Pharmaceutical Co., Ltd / Beijing Hanmei Pharmaceutical Co., Ltd is in the review and approval (in the drug review center) 10 injections have been evaluated, and 9 major products of pharmaceutical enterprises have been "clustered" At present, there are 10 injections that have passed or deemed to pass the consistency evaluation, among which the most antitumor drugs are 4 In addition to Taxol (white protein binding type) for injection, Jiangsu Hengrui Pharmaceutical Co., Ltd In addition to two reviews of Ouyi Pharmaceutical Co., Ltd of Shiyao group, only one of the other nine injections has been reviewed From the perspective of registration classification, more products are approved according to the new registration classification Recently, the application for listing ketorolac tromethamine injection of Chengdu Beite Pharmaceutical Co., Ltd was approved with three types of imitations, and it was deemed to have passed the consistency evaluation It is worth noting that azithromycin for injection of Hainan Puli Pharmaceutical Co., Ltd has applied for evaluation through consistency evaluation, and this product belongs to the common production line at home and abroad Evaluation of supplementary application for injection conformity evaluation (4 enterprises and above) since this year, the evaluation of injection conformity is gradually speeding up In March, CDE released the list of reference preparations of the 21st batch of generic drugs, involving 327 drugs, 242 of which are injections, involving 88 varieties; in June, CDE released the list of reference preparations of the 22nd batch of generic drugs, involving 495 drugs, 231 of which are injections / injections, involving 82 varieties At present, there are 92 supplementary applications for consistency evaluation of injection products in the review and approval (in the drug review center), among which 9 products including ceftriaxone sodium for injection, ropivacaine hydrochloride injection, parecoxib sodium for injection, dexmedetomidine hydrochloride injection involve 4 or more enterprises.